Raised plasma endothelin in unstable angina and non-Q wave myocardial infarction: relation to cardiovascular outcome.

I Wieczorek, W G Haynes, D J Webb, C A Ludlam, K A Fox

Cardiovascular Research Unit, University of Edinburgh.

BACKGROUND--Among patients with independent evidence of coronary disease and recent onset unstable angina or non-Q wave myocardial infarction the incidence of subsequent cardiovascular events is high. Markers predictive of adverse cardiac outcome in unstable angina and non-Q wave myocardial infarction need to be defined more accurately. Endothelin-1 is a potent endothelium derived vasoconstrictor peptide that may play a part in the pathophysiology of acute myocardial ischaemia. AIM AND STUDY DESIGN--In a study that specifically identified high risk patients a group of 16 consecutive patients with either unstable angina at rest or non-Q wave myocardial infarction were prospectively investigated to establish whether these conditions are associated with high plasma immunoreactive endothelin and whether endothelin concentration at presentation is related to cardiovascular events within the next 12 weeks. Controls consisted of a group of 40 healthy subjects. RESULTS--Patients had significantly higher mean (SD) plasma endothelin at presentation than did healthy controls (7.4 (1.1) v 5.0 (1.2) pg/ml, P < 0.0001). At nine weeks plasma endothelin was still significantly higher in those patients who had subsequent cardiovascular events, (n = 9, acute myocardial infarction or refractory angina with electrocardiographic changes and revascularisation procedures, 8.5 (2.6) pg/ml, P < 0.005 v controls) whereas its concentration returned to normal in those patients who had a favourable outcome (n = 7, 5.9 (0.7) pg/ml). Compared with those patients who had an uneventful course, patients with subsequent events had significantly higher plasma endothelin, both at presentation and at nine weeks (P < 0.05 on both occasions). IMPLICATIONS--Endothelin may contribute to the pathophysiology of acute coronary syndromes and may relate to subsequent cardiovascular outcome.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• McNair, L. L., Salamanca, D. A., Khalil, R. A. (2004). Endothelin-1 Promotes Ca2+ Antagonist-Insensitive Coronary Smooth Muscle Contraction Via Activation of {epsilon}-Protein Kinase C. Hypertension 43: 897-904 [Abstract] [Full Text]  
• Mangiafico, R. A., Malatino, L. S., Attina, T., Messina, R., Fiore, C. E. (2002). Exaggerated Endothelin Release in Response to Acute Mental Stress in Patients with Intermittent Claudication. ANGIOLOGY 53: 383-390 [Abstract]  
• Zouridakis, E.G., Schwartzman, R., Garcia-Moll, X., Cox, I.D., Fredericks, S., Holt, D.W., Kaski, J.C. (2001). Increased plasma endothelin levels in angina patients with rapid coronary artery disease progression. Eur Heart J 22: 1578-1584 [Abstract]  
• Gumina, R. J., Moore, J., Schelling, P., Beier, N., Gross, G. J. (2001). Na+/H+ exchange inhibition prevents endothelial dysfunction after I/R injury. Am. J. Physiol. Heart Circ. Physiol. 281: H1260-H1266 [Abstract] [Full Text]  
• Sigurdsson, A., Eriksson, S.V., Hall, C., Kahan, T., Swedberg, K. (2001). Early neurohormonal effects of trandolapril in patients with left ventricular dysfunction and a recent acute myocardial infarction: a double-blind, randomized, placebo-controlled multicentre study. Eur J Heart Fail 3: 69-78 [Abstract] [Full Text]  
• Talbodec, A., Berkane, N., Blandin, V., Breittmayer, J. P., Ferrari, E., Frelin, C., Vigne, P. (2000). Aspirin and Sodium Salicylate Inhibit Endothelin ETA Receptors by an Allosteric Type of Mechanism. Mol. Pharmacol. 57: 797-804 [Abstract] [Full Text]  
• Yeghiazarians, Y., Braunstein, J. B., Askari, A., Stone, P. H. (2000). Unstable Angina Pectoris. NEJM 342: 101-114 [Full Text]  
• Henrion, D., Iglarz, M., Levy, B. I. (1999). Chronic Endothelin-1 Improves Nitric Oxide–Dependent Flow-Induced Dilation in Resistance Arteries From Normotensive and Hypertensive Rats. Arterioscler. Thromb. Vasc. Bio. 19: 2148-2153 [Abstract] [Full Text]  
• Zhang, Y., Oliver, J. R., Horowitz, J. D. (1998). Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist. Cardiovasc Res 39: 665-673 [Abstract] [Full Text]  
• Wilbert-Lampen, U., Seliger, C., Zilker, T., Arendt, R. M. (1998). Cocaine Increases the Endothelial Release of Immunoreactive Endothelin and Its Concentrations in Human Plasma and Urine : Reversal by Coincubation With {sigma}-Receptor Antagonists. Circulation 98: 385-390 [Abstract] [Full Text]  
• Sudhir, K., Ko, E., Zellner, C., Wong, H. E., Hutchison, S. J., Chou, T. M., Chatterjee, K. (1997). Physiological Concentrations of Estradiol Attenuate Endothelin 1–Induced Coronary Vasoconstriction In Vivo. Circulation 96: 3626-3632 [Abstract] [Full Text]  
• Pernow, J., Wang, Q.-D. (1997). Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res 33: 518-526 [Abstract]  
• Pernow, J., Kaijser, L., Lundberg, J. M., Ahlborg, G. (1996). Comparable Potent Coronary Constrictor Effects of Endothelin-1 and Big Endothelin-1 in Humans. Circulation 94: 2077-2082 [Abstract] [Full Text]  
• Haynes, W. G., Ferro, C. J., O'Kane, K. P. J., Somerville, D., Lomax, C. C., Webb, D. J. (1996). Systemic Endothelin Receptor Blockade Decreases Peripheral Vascular Resistance and Blood Pressure in Humans. Circulation 93: 1860-1870 [Abstract] [Full Text]  
• (1995). Plasma Endothelin as a Predictor of Outcome in Unstable Angina. Journal Watch Cardiology 1995: 11-11 [Full Text]